• 1
    Tisdale MJ. Biology of cachexia. J Natl Cancer Inst 1997;89: 176373.
  • 2
    Inui A. Cancer anorexia-cachexia syndrome: are neuropeptides the key? Cancer Res 1999;59: 4493501.
  • 3
    Strassmann G, Jacob CO, Evans R, Beall D, Fong M. Mechanisms of experimental cancer cachexia. Interaction between mononuclear phagocytes and colon-26 carcinoma and its relevance to IL-6-mediated cancer cachexia. J Immunol 1992;148: 36748.
  • 4
    Fujita J, Tsujinaka T, Yano M, et al. Anti-interleukin-6 receptor antibody prevents muscle atrophy in colon-26 adenocarcinoma-bearing mice with modulation of lysosomal and ATP-ubiquitin-dependent proteolytic pathways. Int J Cancer 1996;68: 63743.
  • 5
    Oka M, Yamamoto K, Takahashi M, et al. Relationship between serum levels of interleukin 6, various disease parameters and malnutrition in patients with esophageal squamous cell carcinoma. Cancer Res 1996;56: 277680.
  • 6
    Cahlin C, Korner A, Axelsson H, Wang W, Lundholm K, Svanberg E. Experimental cancer cachexia: the role of host-derived cytokines interleukin (IL)-6, IL-12, interferon-gamma and tumor necrosis factor alpha evaluated in gene knockout, tumor-bearing mice on C57 Bl background and eicosanoid-dependent cachexia. Cancer Res 2000;60: 548893.
  • 7
    Kurebayashi J, Yamamoto S, Otsuki T, Sonoo H. Medroxyprogesterone acetate inhibits interleukin 6 secretion from KPL-4 human breast cancer cells both in vitro and in vivo: a possible mechanism of the anticachectic effect. Br J Cancer 1999;79: 6316.
  • 8
    Iizuka N, Miyamoto K, Kayano K, Hayashi H, Tangoku A, Oka M. The enhancement of cisplatin-induced antitumor activity by Kampo medicines in human esophageal cancer [in Japanese with English abstract]. J Trad Med 1998;15: 3401.
  • 9
    Iizuka N, Miyamoto K, Okita K, et al. Inhibitory effect of Coptidis rhizoma and berberine on the proliferation of human esophageal cancer cell lines. Cancer Lett 2000;148: 1925.
  • 10
    Iizuka N, Miyamoto K, Hazama S, et al. Anticachectic effects of Coptidis rhizoma, an anti-inflammatory herb, on esophageal cancer cells that produce interleukin 6. Cancer Lett 2000;158: 351.
  • 11
    Fujimoto-Ouchi K, Tamura S, Mori K, Tanaka Y, Ishitsuka H. Establishment and characterization of cachexia-inducing and -non-inducing clones of murine colon 26 carcinoma. Int J Cancer 1995;61: 5228.
  • 12
    Fukutake M, Yokota S, Kawamura H, et al. Inhibitory effect of Coptidis rhizoma and Scutellariae radix on azoxymethane-induced aberrant crypt foci formation in rat colon. Biol Pharm Bull 1998;21: 8147.
  • 13
    Yoshimura K, Hazama S, Iizuka N, et al. Successful immunogene therapy using colon cancer cells (colon 26) transfected with plasmid vector containing mature interleukin-18 cDNA and the Igkappa leader sequence. Cancer Gene Ther 2001;8: 916.
  • 14
    Bing C, Brown M, King P, Collins P, Tisdale MJ, Williams G. Increased gene expression of brown fat uncoupling protein (UCP)1 and skeletal muscle UCP2 and UCP3 in MAC16-induced cancer cachexia. Cancer Res 2000;60: 240510.
  • 15
    Iizuka N, Oka M, Noma T, Nakazawa A, Hirose K, Suzuki T. NM23-H1 and NM23-H2 messenger RNA abundance in human hepatocellular carcinoma. Cancer Res 1995;55: 6527.
  • 16
    Ozaki M, Suzuki H, Satake M. Comparative studies on concentration of berberine in plasma after oral administration of Coptidis rhizoma extract, its cultured cells extract and combined use of these extracts and glycyrrhizae radix extract in rats [in Japanese with English abstract]. Yakugaku Zasshi 1993;113: 639.
  • 17
    Fujiki F, Mukaida N, Hirose K, et al. Prevention of adenocarcinoma colon 26-induced cachexia by interleukin 10 gene transfer. Cancer Res 1997;57: 949.
  • 18
    Li XK, Motwani M, Tong W, Bornmann W, Schwartz GK. Huanglian, a Chinese herbal extract, inhibits cell growth by suppressing the expression of cyclin B1 and inhibiting CDC2 kinase activity in human cancer cells. Mol Pharmacol 2000;58: 128793.
  • 19
    Mori K, Fujimoto-Ouchi K, Ishikawa T, Sekiguchi F, Ishitsuka H, Tanaka Y. Murine interleukin-12 prevents the development of cancer cachexia in a murine model. Int J Cancer 1996;67: 84955.
  • 20
    Strassmann G, Masui Y, Chizzonite R, Fong M. Mechanisms of experimental cancer cachexia. Local involvement of IL-1 in colon-26 tumor. J Immunol 1993;150: 23415.
  • 21
    Fukuda K, Hibiya Y, Mutoh M, Koshiji M, Akao S, Fujiwara H. Inhibition of activator protein 1 activity by berberine in human hepatoma cells. Planta Med 1999;65: 3813.
  • 22
    Hussey HJ, Todorov PT, Field WN, et al. Effect of a fluorinated pyrimidine on cachexia and tumour growth in murine cachexia models: relationship with a proteolysis inducing factor. Br J Cancer 2000;83: 5662.
  • 23
    Lorite MJ, Cariuk P, Tisdale MJ. Induction of muscle protein degradation by a tumour factor. Br J Cancer 1997;76: 103540.
  • 24
    Miura N, Yamamoto M, Ueki T, Kitani T, Fukuda K, Komatsu Y. Inhibition of thymocyte apoptosis by berberine. Biochem Pharmacol 1997;53: 131522.
  • 25
    Hakamatsuka T, Tanaka N. Screening for bioactive compounds targeting the cellular signal transduction pathway using an RT-PCR-based bioassay system. Biol Pharm Bull 1997;20: 4646.
  • 26
    Stermitz FR, Lorenz P, Tawara JN, Zenewicz LA, Lewis K. Synergy in a medicinal plant: antimicrobial action of berberine potentiated by 5′-methoxyhydnocarpin, a multidrug pump inhibitor. Proc Natl Acad Sci USA 2000;97: 14337.